Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“New Year reflections in breast oncology!
The 2025 CDK4/6 inhibitor data are reassuring us as oncologists that our adjuvant strategy is worth it — clinically and meaningfully for patients. Hope to give more updates regarding my impressions of the data as a community based breast focused medical oncologist.
Ribociclib (NATALEE)
At 5 years, iDFS 85.5% vs 81.0% (HR 0.716) — durable prevention of recurrence and metastatic disease.
Abemaciclib (monarchE)
Now showing overall survival benefit with a ~16% reduction in risk of death (HR 0.842).
Why this matters:
We ask patients to accept treatment duration, side effects, and financial toxicity in the adjuvant setting. These data reassure us that:
- We are preventing metastatic recurrence
- Patients are living longer
- More patients are living without metastatic disease
Grateful to discuss the NATALEE 5-year data at SABCS2025 with OncUpdates and Oncology Brothers, and to see the CDK4/6 story continue to mature with outcomes that truly matter to patients. Check out my interview with Komal Jhaveri, MD FACP, FASCO below!”
More posts from SABCS 2025.